A feasibility randomized controlled trial published January 27, 2026 in Frontiers in Aging Neuroscience found that a structured, home-based support program for family caregivers of people with Alzheimer's disease could be delivered and largely completed over three months, with caregivers in the intervention group showing significant post-intervention improvements in disease-knowledge scores, anxiety levels, and the psychological domain of a quality-of-life scale compared with baseline, according to the study by Hongli Liu and colleagues at Chongqing General Hospital and Zunyi Medical University in China. The trial enrolled 61 primary family caregivers, randomizing 31 to the new home-care protocol and 30 to a control group receiving conventional nursing guidance consisting of an initial WeChat contact, standardized discharge education, a one-month telephone follow-up, and a three-month home visit.

The program itself was built through a systematic literature review and a two-round Delphi consensus process involving 18 experts, who reached strong agreement on its content, the paper reports. To keep caregivers engaged, the research team offered free MRI scans to patients and caregivers, remote booster check-ins by WeChat every three weeks, and flexible evening or weekend scheduling in either individual or group formats. The study's overall attrition rate was 15.28 percent: of 72 dyads initially assessed for eligibility, 61 were randomized, and 11 were subsequently lost to follow-up, most commonly because of a caregiver's or patient's declining health, a caregiver's own cognitive impairment, a patient's transfer to a nursing home, or one participant's death during the study period, along with a small number of voluntary withdrawals.

The authors describe the program as feasible and preliminarily effective, but they frame the results as a first step rather than proof the intervention works. This was a small, single-country feasibility trial designed chiefly to test whether the program could be delivered and completed, not a large efficacy trial, and the authors themselves call for larger-scale trials before any claim about clinical benefit can be made.